According to the information on the official website of the State Drug Administration, the first anti-cancer yttrium drug product in China, SIR-Spheres yttrium [90Y] microsphere injection, has been officially approved for marketing on February 9. The drug is manufactured by Broad Pharma and is suitable for some patients with colorectal cancer liver metastases.
According to the International Agency for Research on Cancer (IARC), more than 550,000 new cases of colorectal cancer on the mainland alone last year, and 280,000 people unfortunately died as a result. According to the traditional treatment method, the 5-year survival rate of patients in the middle and advanced stages is only 12%, while the 5-year survival rate of anti-cancer yttrium drugs can be improved to about 70%.
Only one treatment is required, anti-cancer nuclear bomb yttrium microspheres
At the end of September last year, at the Hainan Boao Super Hospital, an expert team led by Academician Dong Jiahong, president of Beijing Tsinghua Changgeng Hospital, completed the first case of licensed yttrium [90Y] microsphere precision interventional surgery in China. After 3 months of intervention, the patient's imaging review results showed that the lesion was completely relieved. In other words, one intervention can be cured within 3 months. It is no wonder that Academician Dong Jiahong compared the yttrium [90Y] microspheres to a "super nuclear bomb" that conquers tumors.
Essentially, yttrium [90Y] microsphere injection is a new radiation technology. Its radiation diameter is only 20 to 40 mm, and after doctors use professional means to send it into the interior of cancer cells, it will release rays with an average distance of 2.5 mm, strictly controlling the "anti-cancer battlefield" inside the cancer cells. Therefore, it can not only accurately destroy cancer cells, but also to a large extent avoid the drawbacks of traditional radiotherapy methods of "killing a thousand enemies and losing eight hundred".
As for the price issue that the public is concerned about, at present, the pharmaceutical company Fangda Pharmaceutical has not given public pricing. Referring to the international quotation of similar products, the industry believes that it is expected to be controlled within 10,000. In other words, the approval of sir-Spheres yttrium [90Y] microsphere injection is likely to mean that some cancer patients only need to spend 10,000 yuan and undergo one treatment to recover in the future.
Relevant research is still advancing, and the scope of application is expected to be broadened
What is even more surprising is that the scope of application of yttrium [90Y] microsphere injection is likely to be more than that of patients with liver metastasis of colorectal cancer indicated at this stage. Whether it is the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)" issued by the Mainland Health Commission, or the recommendations of the European and American Cancer Associations, it is believed that it also has excellent potential in the response to other cancers. At present, the FDA has approved the relevant experiments. In the near future, it is expected to help more people with cancer.
In fact, with the advancement of biotechnology, not only everything may start from 2013, Professor Sinclair, director of harvard's Paul.F Aging Research Center, found in experiments that additional supplements with coenzyme I. ("Palovir PRO" core substance) can reverse aging indicators such as hair and muscle energy.
According to the domestic frontier science popularization team "Time School", since Professor Sinclair's relevant papers were unveiled in Cell, top universities such as the University of Washington have carried out research on it. Referring to the paper published in Nature, using its intervention for 3 months, the physiological age of the elderly volunteers returned by nearly 20%. As the first to discover its potential, Professor Sinclair was also named to Time Magazine's "2014 Top 100 Influential People" for his outstanding contributions.
In recent years, with the further maturity of scientific research and preparation technology, the relevant landing results "Palovi PRO" have greatly lowered the threshold and gradually left the circle. Referring to jd.com's tens of thousands of reviews, it has performed extraordinaryly in helping healthy aging. At present, domestic universities such as Qingbei have also begun to enter the research of the substance, or bring us more surprises in the future.
Cancer will be like a cold and can be easily cured
Twenty-three years ago, in most people's cognition, cancer was still an incurable disease, and it was nonsense to fight against aging. However, the progress of science and technology has made everything more possible.
In the middle of last year, the domestic anti-cancer needle Agironse injection was officially approved for listing; at the end of last year, the anti-cancer boron drug BNCT announced the success of the pilot test and is expected to be officially listed within 3 years; now, the yttrium [90Y] microsphere injection for precision sniping cancer cells has been approved for listing. Blowouts of scientific technology are making cancer cures easier and simpler. At the same time, getting old also encountered the palliative program of Perovi PRO.
Wall Street brokerage Bank of America Merrill Lynch found as early as 2019 that it only takes 73 days for the total amount of modern biotechnology to double. In the past, this time period was 3 years. Analysts predict that we are entering a whole new era. If this trend continues, it won't be long before cancer, or even getting older, will be what we expect.